Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed an 8-K current report with the SEC on October 29, 2026 reporting Item 1.02 (Termination of a Material Definitive Agreement). Bristol Myers Squibb ending PRX019 development after Phase 1, despite benign safety and dose-dependent pharmacodynamic results.
PROTHENA CORP PUBLIC LTD CO 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.02 · Termination of a Material Definitive Agreement
- Bristol Myers Squibb ending PRX019 development after Phase 1, despite benign safety and dose-dependent pharmacodynamic results
- PRX019 license terminates January 28, 2027, eliminating eligibility for up to $617.5 million in milestones and future royalties
- Prothena retains the $80 million upfront payment received under the 2024 agreement
- Strategic focus shifts toward moponetug, Bristol Myers Squibb’s ongoing Phase 2 Alzheimer’s program
- Moponetug generated $135 million in licensing payments, with up to $562.5 million milestones plus tiered royalties remaining available
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other PROTHENA CORP PUBLIC LTD CO 8-K filings
Get the next PRTA 8-K as it lands
Follow PRTA for push alerts, or ask the research agent what this filing means.